Abstracts presented at SfN Neuroscience 2019 provide insight into how gene therapy advancements could be used treat diseases such as Parkinson’s and Alzheimer’s in the future.
Browsing: neurodegenerative disease
What are the challenges surrounding clinical trial design for genetic therapies in terms of neurodegenerative diseases? What technological advances could help bring these therapies to the clinic more quickly? Find out in our video interview with Sarah Tabrizi.
Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
Researchers have found that the sleep history and pattern of older men and women may predict the accumulation of proteins associated with Alzheimer’s disease.
To mark World Parkinson’s Day, we’re taking the opportunity to look back on some of the research highlights in the field over the last year.
Scientists have 3D printed a transparent skull implant for mice, creating a ‘window’ to the brain for monitoring brain surface activity in real time. The implant could provide unique opportunities for research into concussions as well as Alzheimer’s and Parkinson’s diseases.
For our Spotlight on biomarker discovery and development we carried out a survey to gain insights into biomarkers used, their challenges and future outlook.
In this report from Future Neurology, researchers describe the application and state of development of a range of CSF biomarkers in common neurodegenerative disorders.
Researchers have identified a simple blood test that may be able to diagnose neurodegeneration before symptoms arise; this could lead to earlier diagnosis of Alzheimer’s disease.